SOURCE: Biotie Therapies Oyj

August 28, 2009 02:25 ET

Biotie Reaches Milestone in Wyeth Collaboration

TURKU, FINLAND--(Marketwire - August 28, 2009) -


Biotie Reaches Milestone in Wyeth Collaboration

Biotie announced today that it has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a USD 1.0 million milestone payment to Biotie.

Timo Veromaa, President and CEO of Biotie said "We are pleased with the progress we have made in collaboration with Wyeth on the PDE10 inhibitor program and look forward to beginning our work together in the clinic. We believe this partnership provides further validation for our PDE platform technology, which has already provided us with one active clinical program and several pre-clinical programs."

PDE10 is a novel CNS drug target that is thought to play an important role in the pathophysiology of schizophrenia. Biotie has demonstrated that inhibitors of PDE10 display promising antipsychotic activity in experimental models, indicating the potential for a superior efficacy and tolerability profile versus current standard therapies. Data from these studies has recently been presented for the first time at the American Chemical Society Fall National Meeting in Washington DC (August 16 - 20). Additional data will also be presented at the Society for Neuroscience Annual Meeting in Chicago, IL (October 17 - 21).

Turku, August 28, 2009

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail:

NASDAQ OMX Helsinki Ltd
Main Media

Biotie Therapies Corp.

Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie's products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.

The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finland and Radebeul, Germany.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.

For more information, please refer to

Biotie agreement with Wyeth

Under the terms of the research collaboration and license agreement between Biotie and Wyeth, Biotie is eligible for up to USD 110 million in funding related to the initial signing fee, research funding and milestone payments. Biotie is also eligible to receive royalties on sales following commercialization.


Schizophrenia is a chronic, severe and disabling disorder of the central nervous system affecting up to one percent of the population. The disease is characterized by hallucinations, social withdrawal, and deficits in cognition and memory. Current treatments are mostly efficacious in the treatment of hallucinations but have insufficient efficacy for social withdrawal and may have intolerable side effects including weight gain, diabetes, movement disorders and anxiety disorders.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information